FDA Responds to Bitopertin Application with Complete Response Letter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy IRON?
Source: Newsfilter
- FDA Response: The FDA acknowledged that AURORA and BEACON trials provided sufficient evidence that Bitopertin significantly lowers PPIX, yet it requires results from the ongoing APOLLO study, indicating a cautious approach towards accelerated approval.
- Clinical Trial Progress: The APOLLO study is underway, with topline data expected in Q4 2026, and Disc Medicine plans to respond to the CRL post-study completion, which could impact the traditional approval pathway for Bitopertin.
- Financial Position: As of December 31, 2025, Disc Medicine reported approximately $791 million in cash and cash equivalents, indicating financial resilience to support operations through 2029 amidst FDA challenges.
- Market Reaction: Although the CRL delays Bitopertin's potential approval, Disc Medicine remains confident in the APOLLO trial, which is expected to garner increased enthusiasm from patients and physicians, thereby strengthening its market position in EPP treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.230
Low
100.00
Averages
120.20
High
154.00
Current: 64.230
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
Pomerantz LLP Investigates Claims on Behalf of Disc Medicine Investors
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors in Disc Medicine, Inc., focusing on whether the company and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Review Delay: On January 15, 2026, it was reported that a drug under development by Disc faced a delay in its review timeline after U.S. FDA scientists flagged safety and efficacy concerns, directly impacting market confidence in the company.
- Significant Stock Price Drop: Following the FDA news, Disc's stock price fell by $6.04, or 7.84%, closing at $71.04 per share, which may have a substantial impact on investors' assets.
- Potential Legal Action Impact: The investigation by Pomerantz LLP, a prominent securities litigation firm, could lead to legal actions against Disc, further affecting shareholder rights and the company's reputation.
See More
Disc Medicine CFO Sells 11,156 Shares Amid FDA Rejection
- Executive Sell-off: Disc Medicine's CFO Jean M. Franchi sold 11,156 shares for approximately $720,000 across three transactions on February 17 and 18, 2026, marking a significant increase from his previous high of 3,136 shares, indicating potential concerns about the company's future.
- Ownership Impact: This transaction accounted for 13.52% of Franchi's direct holdings, suggesting a possible lack of confidence in the company's outlook, especially following the FDA's rejection of its key drug, bitopertin.
- Financial Overview: With a market capitalization of $2.51 billion, Disc Medicine has seen its stock decline approximately 15% in 2026, despite three years of consecutive price growth, reflecting investor concerns over its financial health as it reported a net loss of $212.18 million.
- Layoffs and Strategic Shift: Following the FDA rejection, Disc Medicine announced a 20% workforce reduction while pursuing alternative approval pathways, a move that could impact operational efficiency and investor confidence.
See More
Disc Medicine CFO Sells Shares, Reduces Holdings
- Executive Share Sale: Jean Franchi, CFO of Disc Medicine, sold 11,156 shares in open-market transactions on February 17 and 18, 2026, for approximately $720,000 at an average price of $64.51 per share, reducing his direct holdings by 13.52% from 82,499 to 71,343 shares, indicating a cautious outlook on the company's future.
- FDA Drug Approval Setback: The company's clinical-stage drug bitopertin was rejected by the FDA on February 13, 2026, primarily due to concerns over trial data and abuse risk, leading to a 15% decline in stock price in 2026, raising fears of further losses.
- Workforce Reduction: In response to the FDA rejection, Disc Medicine announced a 20% workforce cut on February 27, 2026, highlighting the urgency of addressing market pressures and financial challenges, as evidenced by a doubling of net losses in its FY 2025 earnings report.
- Investor Caution: Despite modest stock gains over the past three years, Disc Medicine was not included in the Motley Fool's current list of top investment stocks, signaling to investors the need for caution when considering investments in the company amid significant challenges.
See More
Disc Medicine Initiates Restructuring Plan with 20% Layoffs
- Restructuring Plan Initiated: Disc Medicine has announced a restructuring plan that includes a 20% workforce reduction, aimed at enhancing operational efficiency in light of recent challenges, particularly following the FDA's Complete Response Letter.
- FDA Response Impact: Earlier this month, the company received a Complete Response Letter from the FDA regarding bitoperin, casting doubt on the future of its APOLLO study and necessitating urgent measures to safeguard its development trajectory.
- Financial Impact Assessment: The company anticipates incurring a $2 million charge related to the restructuring, primarily for severance costs, which will exert pressure on its short-term financials but is expected to facilitate long-term sustainability.
- Market Reaction: Disc Medicine reported a GAAP EPS of -$6.01, reflecting a significant decline in stock price following the FDA's Complete Response Letter, indicating a severe loss of market confidence in its future prospects.
See More
Disc Medicine Reports FY Loss and Cash Position Improvement
- Financial Loss: Disc Medicine's FY report reveals a GAAP EPS of -$6.01 for 2025, indicating ongoing investments in R&D and operations, which, while necessary for future growth, contribute to current financial strain.
- Cash Position Improvement: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $791.2 million, up from $489.9 million in 2024, primarily due to net proceeds of $454.4 million from underwritten offerings in January and October 2025, showcasing successful fundraising efforts.
- Operating Cash Flow: Despite the increase in cash reserves, the company utilized cash in operating activities, highlighting the need for Disc Medicine to focus on cost control and cash flow management while advancing its R&D and market strategies to ensure sustainable growth.
- FDA Review Challenges: The company faces challenges from an FDA Complete Response Letter that casts doubt on the regulatory approval path for Bitopertin, potentially impacting market prospects and investor confidence, especially as delays are also reported in its collaboration with Sanofi.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
Pomerantz LLP Investigates Claims on Behalf of Disc Medicine Investors
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors in Disc Medicine, Inc., focusing on whether the company and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Review Delay: On January 15, 2026, it was reported that a drug under development by Disc faced a delay in its review timeline after U.S. FDA scientists flagged safety and efficacy concerns, directly impacting market confidence in the company.
- Significant Stock Price Drop: Following the FDA news, Disc's stock price fell by $6.04, or 7.84%, closing at $71.04 per share, which may have a substantial impact on investors' assets.
- Potential Legal Action Impact: The investigation by Pomerantz LLP, a prominent securities litigation firm, could lead to legal actions against Disc, further affecting shareholder rights and the company's reputation.
See More
Disc Medicine CFO Sells 11,156 Shares Amid FDA Rejection
- Executive Sell-off: Disc Medicine's CFO Jean M. Franchi sold 11,156 shares for approximately $720,000 across three transactions on February 17 and 18, 2026, marking a significant increase from his previous high of 3,136 shares, indicating potential concerns about the company's future.
- Ownership Impact: This transaction accounted for 13.52% of Franchi's direct holdings, suggesting a possible lack of confidence in the company's outlook, especially following the FDA's rejection of its key drug, bitopertin.
- Financial Overview: With a market capitalization of $2.51 billion, Disc Medicine has seen its stock decline approximately 15% in 2026, despite three years of consecutive price growth, reflecting investor concerns over its financial health as it reported a net loss of $212.18 million.
- Layoffs and Strategic Shift: Following the FDA rejection, Disc Medicine announced a 20% workforce reduction while pursuing alternative approval pathways, a move that could impact operational efficiency and investor confidence.
See More
Disc Medicine CFO Sells Shares, Reduces Holdings
- Executive Share Sale: Jean Franchi, CFO of Disc Medicine, sold 11,156 shares in open-market transactions on February 17 and 18, 2026, for approximately $720,000 at an average price of $64.51 per share, reducing his direct holdings by 13.52% from 82,499 to 71,343 shares, indicating a cautious outlook on the company's future.
- FDA Drug Approval Setback: The company's clinical-stage drug bitopertin was rejected by the FDA on February 13, 2026, primarily due to concerns over trial data and abuse risk, leading to a 15% decline in stock price in 2026, raising fears of further losses.
- Workforce Reduction: In response to the FDA rejection, Disc Medicine announced a 20% workforce cut on February 27, 2026, highlighting the urgency of addressing market pressures and financial challenges, as evidenced by a doubling of net losses in its FY 2025 earnings report.
- Investor Caution: Despite modest stock gains over the past three years, Disc Medicine was not included in the Motley Fool's current list of top investment stocks, signaling to investors the need for caution when considering investments in the company amid significant challenges.
See More
Disc Medicine Initiates Restructuring Plan with 20% Layoffs
- Restructuring Plan Initiated: Disc Medicine has announced a restructuring plan that includes a 20% workforce reduction, aimed at enhancing operational efficiency in light of recent challenges, particularly following the FDA's Complete Response Letter.
- FDA Response Impact: Earlier this month, the company received a Complete Response Letter from the FDA regarding bitoperin, casting doubt on the future of its APOLLO study and necessitating urgent measures to safeguard its development trajectory.
- Financial Impact Assessment: The company anticipates incurring a $2 million charge related to the restructuring, primarily for severance costs, which will exert pressure on its short-term financials but is expected to facilitate long-term sustainability.
- Market Reaction: Disc Medicine reported a GAAP EPS of -$6.01, reflecting a significant decline in stock price following the FDA's Complete Response Letter, indicating a severe loss of market confidence in its future prospects.
See More
Disc Medicine Reports FY Loss and Cash Position Improvement
- Financial Loss: Disc Medicine's FY report reveals a GAAP EPS of -$6.01 for 2025, indicating ongoing investments in R&D and operations, which, while necessary for future growth, contribute to current financial strain.
- Cash Position Improvement: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $791.2 million, up from $489.9 million in 2024, primarily due to net proceeds of $454.4 million from underwritten offerings in January and October 2025, showcasing successful fundraising efforts.
- Operating Cash Flow: Despite the increase in cash reserves, the company utilized cash in operating activities, highlighting the need for Disc Medicine to focus on cost control and cash flow management while advancing its R&D and market strategies to ensure sustainable growth.
- FDA Review Challenges: The company faces challenges from an FDA Complete Response Letter that casts doubt on the regulatory approval path for Bitopertin, potentially impacting market prospects and investor confidence, especially as delays are also reported in its collaboration with Sanofi.
See More
